A | IF THE TRIALS THAT ARE IN PROGRESS NOW FAIL, the public may criticize drugmakers regarding their failed risk assessments and a lack of up-front transparency about those risks. In fact, I’d say that my biggest concern is that transparency when effectively communicating the known risks of these studies. On the other hand, anecdotally, I’ve spoken to some people, HCPs included, that say they would not get the vaccine when it first becomes available by the end of the year because they are concerned that it was rushed, and the safety profile would not be well-established. It seems to me that the public perception of the industry will suffer either way.
MITCHELL KATZ, PH.D., is VP of development operations at Ferring Pharmaceuticals. He has 30 years of experience in the pharmaceutical and biotechnology industries.